Condition: Major Depressive Disorder · Chronic Major Depression, Recurrent · Sponsor: University of Texas at Austin
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
This description comes directly from the study's public registry record.
Greg Fonzo, Ph.D. · 512-495-5856 · fonzolab@austin.utexas.edu
Lauren Enten, B.S.A · lauren.enten@austin.utexas.edu
Always discuss trial participation with your own doctor first.
| Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05892744